8-hydroxy quinoline derivatives

Abstract

The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.

1 .- 14 . (canceled) 
     
     
         15 . A method for the treatment of Huntington's disease in a subject which comprises administering to the subject a therapeutically effective amount of a compound of the formula 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salts thereof, in which
 R 1  is H; 
 R 2  is optionally substituted phenyl; optionally substituted naphthyl; optionally substituted tetrahydronaphthyl; optionally substituted biphenyl; optionally substituted heterocyclyl; COR 6 ; CSR 6 ; CN; (CH 2 )NR 9 R 10 ; HCNOR 9 ; HCNNR 9 R 10 ; OR 11 ; SR 11 ; NR 11 R 12  or SO 2 NR 13 R 14 ; in which R 13  and R 14  are either the same or different and selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heterocyclyl; and 
 R 6  is H, C 1-6  alkyl, optionally substituted C 2-6  alkenyl, hydroxy, optionally substituted aryl, optionally substituted heterocyclyl, SR 7  or NR 7 R 8 ; 
 R 7  and R 8  are either the same or different and selected from H, optionally substituted C 1-6  alkyl, optionally substituted C 2-6  alkenyl, optionally substituted aryl and optionally substituted heterocyclyl; 
 R 9  is H, optionally substituted C 1-6  alkyl, optionally substituted C 2-6  alkenyl, optionally substituted aryl or optionally substituted heterocyclyl; 
 R 10  is hydrogen, methyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, optionally substituted C 2-6  alkenyl, optionally substituted aryl or optionally substituted heterocyclyl; 
 R 11  is H, optionally substituted C 1-6  alkyl, optionally substituted C 2-6  alkenyl, optionally substituted aryl or optionally substituted heterocyclyl or together with R 12  form optionally substituted heterocyclyl; 
 R 12  is optionally substituted C 1-6  alkyl, optionally substituted C 2-6  alkenyl, optionally substituted aryl or optionally substituted heterocyclyl or together with R 11  form optionally substituted heterocyclyl; 
 R 3 , R and R′ are either the same or different and selected from H, optionally substituted C 1-6  alkyl, optionally substituted C 2-6  alkenyl, optionally substituted C 1-6  alkoxy, optionally substituted acyl, hydroxy, optionally substituted amino, optionally substituted thio, optionally substituted sulphonyl, optionally substituted sulphinyl, optionally substituted sulphonylamino, halo, SO 3 H, amine, CN, CF 3 , optionally substituted aryl and optionally substituted heterocyclyl; and 
 R 4  and R 5  are chloro, 
 wherein the optional substituent is C 1-6  alkyl, CF 3 , fluorine, chlorine, iodine, cyano, C 1-6  alkoxy, 5 or 6-membered aryl, heteroaryl, amino or C 1-6  alkylamino. 
 
     
     
         16 . The method according to  claim 15 , in which either R 2  is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted tetrahydronapthyl, optionally substituted biphenyl, optionally substituted heterocyclyl, CH 2 NR 9 R 10  or COR 6  or at least one of R, R 3  and R′ is optionally substituted C 1-6  alkyl, optionally substituted aryl, optionally substituted heterocyclyl, CH 2 NR 9 R 10  or COR 6  in which R 6  is NR 7 R 8  or NR 11 R 12 . 
     
     
         17 . The method of  claim 15 , in which the compound of formula I is 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salts thereof. 
     
     
         18 . The method of  claim 15 , in which the compound is administered in association with a pharmaceutically acceptable carrier. 
     
     
         19 . The method of  claim 15 , in which the compound is administered in association with a medicament, said medicament being an inhibitor of the acetyl cholinesterase active site, an antioxidant, an anti-inflammatory agent or an oestrogenic agent. 
     
     
         20 . The method of  claim 15 , in which the compound is in hydrate form.